The effectiveness of conjugate haemophilus influenzae type b vaccine in the gambia 14 years after introduction

Clinical Infectious Diseases

Volumn 57, Issue 11, 2013, Pages 1527-1534

  Howie, Stephen R C ^a   Oluwalana, Claire ^a   Secka, Ousman ^a   Scott, Susana ^a,b   Ideh, Readon C ^a   Ebruke, Bernard E ^a   Balloch, Anne ^c   Sambou, Sana ^d   Erskine, James ^e   Lowe, Yamundow ^a   Corrah, Tumani ^e   Adegbola, Richard A ^a,f  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d MINISTRY OF HEALTH AND SOCIAL WELFARE   (Gambia)

^e WEC Mission Hospital   (Gambia)

^f GSK   (Belgium)

Author keywords

Africa; Gambia; Hib disease; Hib vaccination; Surveillance

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

ARTICLE; DISEASE SURVEILLANCE; DRUG EFFICACY; FEMALE; GAMBIA; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS MENINGITIS; HEALTH CARE SURVEY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VACCINATION;

AFRICA; GAMBIA; HIB DISEASE; HIB VACCINATION; SURVEILLANCE;

CARRIER STATE; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; GAMBIA; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; INFANT; MASS VACCINATION; PUBLIC HEALTH SURVEILLANCE; VACCINES, CONJUGATE;

EID: 84887916602     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit598     Document Type: Article

References (37)

1. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13: 302-17.
2. Adegbola RA, Secka O, Lahai G., et al Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005; 366: 144-50.
3. Oluwalana C, Howie SRC, Secka O, et al Incidence of Haemophilus influenzae type b disease in The Gambia 14 years after Introduction of routine Haemophilus influenzae type b conjugate vaccine immunization. J Pediatr 2013. In press.
4. International Vaccine Access Centre. VIMS Report: global vaccine introduction, 2012. Available at: http://wwwjhsphedu/research/centers-and- institutes/ivac/vims/IVAC-VIMS-Report-2012-08pdf. Accessed 12 March 2013.
5. World Health Organization. Countries having introduced Hib vaccine in 1997 and 2010. Available at: http://www.whoint/nuvi/hib/decision-implementation/ en/index1html. Accessed 11 March 2013.
6. World Health Organization. Number of countries having introduced Hib (containing) vaccines to date. 2012. Available at: http://www.whoint/nuvi/hib/ decision-implementation/en/index1html. Accessed 11 March 2013.
7. CEPA LLP. GAVI second evaluation report 2010. Available at: http://www.gavialliance.org/resources/GAVI-Second-Evaluation-Report-Final- 13Sep2010.pdf. Accessed 3 June 2011.
8. Ojo LR, O'Loughlin RE, Cohen AL, et al Global use of Haemophilus influenzae type b conjugate vaccine. Vaccine 2010; 28: 7117-22.
9. Watt J, Chen S, Santosham M. Haemophilus influenzae type b conjugate vaccine: review of observational data on long term vaccine impact to inform recommendations for vaccine schedules. Report for World Health Organization, 2012.
10. World Health Organization. Immunization surveillance, assessment and monitoring: Haemophilus influenzae type b (Hib). 2011. Available at: http://www.whoint/immunization-monitoring/diseases/Hib/en/. Accessed 11 March 2011.
11. Madore DV, Anderson P, Baxter B.D., et al Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 1996; 3: 84-8.
12. Phipps DC, West J, Eby R., Koster M, Madore DV, Quataert SA An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J Immunol Methods 1990; 135: 121-8.
13. Pietrzyk JJ, Wysocki J, Pejcz J., et al Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age. Vaccine 2008; 26: 5296-303.
14. Southern J, McVernon J, Gelb D., et al Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. Clin Vaccine Immunol 2007; 14: 1328-33.
15. World Health Organization. Immunization coverage cluster survey-reference manual. 2005. Report reference WHO/IVB/0423. Available at: www.whoint/vaccines- documents/.
16. Booy R, Heath PT, Slack M.P., Begg N., Moxon ER Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster. Lancet 1997; 349: 1197-202.
17. Clements DA, Booy R, Dagan R., et al Comparison of the epidemiology and cost of Haemophilus influenzae type b disease in five western countries. Pediatr Infect Dis J 1993; 12: 362-7.
18. von Gottberg A., de Gouveia L, Madhi SA, et al Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa. Bull World Health Organ 2006; 84: 811-8.
19. von Gottberg A., Cohen C, Whitelaw A., et al Invasive disease due to Haemophilus influenzae serotype b ten years after routine vaccination, South Africa, 2003-2009. Vaccine 2012; 30: 565-71.
20. Akumu AO, English M, Scott J.A., Griffiths UK Economic evaluation of delivering Haemophilus influenzae type b vaccine in routine immunization services in Kenya. Bull World Health Organ 2007; 85: 511-8.
21. McCormick DW, Molyneux EM Bacterial meningitis and Haemophilus influenzae type b conjugate vaccine, Malawi. Emerg Infect Dis 2011; 17: 688-90.
22. Garcia S, Lagos R, Munoz A., et al Impact of vaccination against Haemophilus influenzae type b with and without a booster dose on meningitis in four South American countries. Vaccine 2012; 30: 486-92.
23. Ribeiro GS, Lima JB, Reis J.N., et al Haemophilus influenzae meningitis 5 years after introduction of the Haemophilus influenzae type b conjugate vaccine in Brazil. Vaccine 2007; 25: 4420-8.
24. Zanella RC, Bokermann S, Andrade A.L., Flannery B., Brandileone MC Changes in serotype distribution of Haemophilus influenzae meningitis isolates identified through laboratory-based surveillance following routine childhood vaccination against H. influenzae type b in Brazil. Vaccine 2011; 29: 8937-42.
25. Ladhani S, Slack MP, Heys M, White J., Ramsay ME Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child 2008; 93: 665-9.
26. McVernon J, Howard AJ, Slack M.P., Ramsay ME Long-term impact of vaccination on Haemophilus influenzae type b (Hib) carriage in the United Kingdom. Epidemiol Infect 2004; 132: 765-7.
27. McVernon J, Andrews N, Slack M.P., Ramsay ME Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003; 361: 1521-3.
28. Heath PT, McVernon J. The UK Hib vaccine experience. Arch Dis Child 2002; 86: 396-9.
29. Fitzgerald M, Canny M, O'Flanagan D. Vaccination catch-up campaign in response to recent increase in Hib infection in Ireland. Euro Surveill 2005; 10: E0509292.
30. Kayhty H, Peltola H, Karanko V., Makela PH The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147: 1100.
31. Gambian National AIDS Secretariat. Country progress report: The Gambia. 2012. Available at: http://wwwunaidsorg/en/dataanalysis/knowyourresponse/ countryprogressreports/2012countries/ce-GM-Narrative-Report%5B1%5Dpdf. Accessed 15 August 2013.
32. Mulholland K, Hilton S, Adegbola R., et al Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997; 349: 1191-7.
33. Gupta SK, Sosler S, Lahariya C. Introduction of Haemophilus influenzae type b (Hib) as pentavalent (DPT-HepB-Hib) vaccine in two states of India. Indian Pediatr 2012; 49: 707-9.
34. Nair H, Hazarika I, Patwari A. A roller-coaster ride: introduction of pentavalent vaccine in India. J Glob Health 2011; 1: 32-5.
35. Hajjeh RA, Privor-Dumm L, Edmond K., et al Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience. Vaccine 2010; 28: 7123-9.
36. Muanya C. Why Nigeria introduced pentavalent vaccine. The Guardian, 2012. Available at: http://www.guardiannewsngr.com/index.php?option=com- content&view=article&id=89146:why-nigeria-introduced-pentavalent- vaccine-&catid=93:science&Itemid=608. Accessed 12 March 2013.
37. World Health Organization. New and Under-utilized Vaccines Implementation (NUVI): invasive Haemophilus influenzae type B (Hib) disease prevention. 2011. Available at: http://www.whoint/nuvi/hib/en/indexhtml. Accessed 12 March 2013.